Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Clinical Course After Initiation of Nivolumab Therapy in Patients with EGFR-Mutated Non-Small Cell Lung Cancer With or Without Pd-L1 Expression

Clinical Course After Initiation of Nivolumab Therapy in Patients with EGFR-Mutated Non-Small... Oncol Ther (2017) 5:181–185 DOI 10.1007/s40487-017-0053-3 BRIEF REPORT Clinical Course After Initiation of Nivolumab Therapy in Patients with EGFR-Mutated Non-Small Cell Lung Cancer With or Without Pd-L1 Expression . . . Minehiko Inomata Hiroaki Tanaka Kotaro Tokui . . . . Chihiro Taka Seisuke Okazawa Kenta Kambara Shingo Imanishi . . . Toru Yamada Toshiro Miwa Ryuji Hayashi Kazuyuki Tobe Received: August 23, 2017 / Published online: October 20, 2017 The Author(s) 2017. This article is an open access publication who had received nivolumab treatment based ABSTRACT on clinical judgment were analyzed retrospec- tively. Tumor PD-L1 expression was evaluated Introduction: Nivolumab has been reported to by measurement of the tumor proportion score be more effective in the subset of non-squa- (TPS) using a rabbit antihuman PD-L1 antibody mous non-small cell lung cancer (NSCLC) (clone 22C3). patients with tumors harboring wild-type epi- Results: Three patients received the treatment dermal growth factor receptor (EGFR) and/or with nivolumab as second line treatment, and expressing programmed death ligand-1 (PD-L1). two patients received the treatment as third line However, it is unclear whether PD-L1 expres- treatment. One out of five patients had a sion influences the efficacy of nivolumab in response with treatment with http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Clinical Course After Initiation of Nivolumab Therapy in Patients with EGFR-Mutated Non-Small Cell Lung Cancer With or Without Pd-L1 Expression

Download PDF
5 pages

Loading next page...
 
/lp/springer-journals/clinical-course-after-initiation-of-nivolumab-therapy-in-patients-with-cht6F4ITOx
Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-017-0053-3
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2017) 5:181–185 DOI 10.1007/s40487-017-0053-3 BRIEF REPORT Clinical Course After Initiation of Nivolumab Therapy in Patients with EGFR-Mutated Non-Small Cell Lung Cancer With or Without Pd-L1 Expression . . . Minehiko Inomata Hiroaki Tanaka Kotaro Tokui . . . . Chihiro Taka Seisuke Okazawa Kenta Kambara Shingo Imanishi . . . Toru Yamada Toshiro Miwa Ryuji Hayashi Kazuyuki Tobe Received: August 23, 2017 / Published online: October 20, 2017 The Author(s) 2017. This article is an open access publication who had received nivolumab treatment based ABSTRACT on clinical judgment were analyzed retrospec- tively. Tumor PD-L1 expression was evaluated Introduction: Nivolumab has been reported to by measurement of the tumor proportion score be more effective in the subset of non-squa- (TPS) using a rabbit antihuman PD-L1 antibody mous non-small cell lung cancer (NSCLC) (clone 22C3). patients with tumors harboring wild-type epi- Results: Three patients received the treatment dermal growth factor receptor (EGFR) and/or with nivolumab as second line treatment, and expressing programmed death ligand-1 (PD-L1). two patients received the treatment as third line However, it is unclear whether PD-L1 expres- treatment. One out of five patients had a sion influences the efficacy of nivolumab in response with treatment with

Journal

Oncology and Therapy – Springer Journals

Published: Oct 20, 2017

References

  • Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
    Brahmer, J; Reckamp, KL; Baas, P
  • Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
    Borghaei, H; Paz-Ares, L; Horn, L
  • Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
    Herbst, RS; Baas, P; Kim, DW
  • EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis
    Gainor, JF; Shaw, AT; Sequist, LV
  • Association between PD-L1 expression and driven gene status in NSCLC: A meta-analysis
    Li, D; Zhu, X; Wang, H; Li, N
  • Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥ 50% expression in lung adenocarcinoma
    Rangachari, D; VanderLaan, PA; Shea, M
  • PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer
    Okita, R; Maeda, A; Shimizu, K; Nojima, Y; Saisho, S; Nakata, M
  • Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation
    Chen, N; Fang, W; Zhan, J